The Experimental Medicine and Immunotherapeutics division has a strong record in clinical research. Our interests are mainly in the field of hypertension and cardiovascular medicine. The clinical trials are run from Level 3 of the Addenbrooke’s Centre for Clinical Investigation (ACCI) from the Clinical Investigation Ward and the Vascular Research Clinics. We run large-scale clinical trials looking at drug therapy in hypertension as well as longitudinal collaborative studies investigating novel risk factors for cardiovascular disease. Past examples of physiological and interventional clinical trials include the AngloCardiff Collaborative Trial (ACCT) studies, PEXIVAS, RITAZAREM and ALEVIATE studies. We are increasingly using imaging modalities such as PET-CT and MRI to understand and characterise cardiovascular conditions such as vascular inflammation, adrenal function and arterial stiffness. We use a number of non-invasive techniques to look at vascular and endothelial function. Some information about PIs interested in clinical research is in the table below. More information about our interests in clinical research may also be found under individual PI pages. Also listed below is a brief summary of current clinical trials / studies within the EMIT Unit. We are also closely associated with the new Cambridge University Health Partners’ Clinical Trials Unit, with one of our PIs being its Director.
Dr Joseph Cheriyan : Director of the Cardiovascular Clinical Trials Office, Cambridge University Hospitals & Vice Chair, Cambridge Central Ethics Committee. Clinical trials / studies to investigate the role of novel therapeutic agents on vascular function.
Dr Carmel McEniery : Detailed physiological phenotyping of the cardiovascular system to understand the factors regulating blood pressure and vascular function in health and disease.
Professor Ian Wilkinson : Director of the new Cambridge University Health Partners’ Clinical Trials Unit. Research interests in physiology and pharmacology of the cardiovascular system, in particular the large arteries.
Dr David Jayne : Director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital
Dr Thomas Hiemstra : Director of clinical trials in patients with impaired kidney function. Research interests include clinical trial design and novel trials methodologies
Current EMIT Clinical Research Studies / Trials
|ACCT||ACCT – The Anglo-Cardiff Collaborative Trial is a series of cross-sectional and longitudinal studies investigating the mechanisms underlying changes in blood pressure and arterial stiffening across the adult age-span. Specific research themes include:
Is isolated systolic hypertension and/or low bone mineral denisty associated with an increase in aortic calcification?
Determining the feasibility of randomisation to high versus ad libitum water intake in Autosomal Dominant Polycystic Kidney Disease: The DRINK Randomised Feasibility Trial
The predictive value of cardiac output and arterial stiffness for future hypertension
|Endothelial Dysfunction in Renal Transplantation||
Does receiving a kidney transplant stimulate the immune system which then contributes to endothelial dysfunction?
Investigating the role of inflammation in the development of complications of lung disease outside of the lung (recruiting patients with COPD).
What is the effect of kidney donation on bone-mineral metabolism and arterial stiffness?
Low dose interleukin-2 in stable ischaemic heart disease and acute coronary syndrome. Using immuno-modulation to treat inflammation in the heart to prevent heart attacks and heart disease progression
Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease. (OPERA-CKD)
Plasma exchange and reduced glucocorticoid dosing in severe ANCA vasculitis
A study of the pharmacokinetic and pharmacodynamic responses in healthy and altered human cardiovascular systems (PRIME)
Rituximab or azathioprine for remission maintenance of ANCA vasculitis
Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women with Preeclampsia via Apheresis Utilizing the Flt-1 Adsorption Column
Phase II dose ranging trial of alemtuzumuab in refractory vasculitis